Dr. Smith's Dashboard

Sunovion Services

Request complimentary samples of LATUDA® (lurasidone HCl) tablets for your patients

ORDER YOUR SAMPLES NOW

Need support? Ask Sunovion Answers for information about LATUDA® (lurasidone HCl)

 

A dedicated team is available 7 days a week, from 8 AM to 12:00 midnight ET, to answer patient's calls at 1-855-552-8832

LEARN MORE

Most Viewed

Efficacy

Offer your patients with bipolar depression proven antidepressant efficacy1

LATUDA monotherapy achieved a 44% greater reduction in depressive symptoms at Week 6 vs placebo

  • In this study LATUDA was superior to placebo in reduction of MADRS scores at Week 61,2
  • The high-dose range (80–120 mg/day) did not provide additional efficacy, on average, compared to the low-dose range (20–60 mg/day)1,2
  • LATUDA was also proven superior to placebo in the key secondary measure of CGI-BP scores1,2

*MADRS=Montgomery-Åsberg Depression Rating Scale.
Mixed model for repeated measures (MMRM) analysis.
Mean baseline MADRS scores: placebo: 30.5, LATUDA 20–60 mg/day: 30.3, and LATUDA 80–120 mg/day: 30.6.
Mean dose (SD) for LATUDA 20–60 mg/day was 31.8 (± 11.1) mg/day.3
Mean dose (SD) for LATUDA 80–120 mg/day was 82.0 (± 13.4) mg/day.3
 

 

Chapter 3: Efficacy

Dr. Joseph R. Calabrese, a psychiatrist specializing in mood disorders, discusses the effect of LATUDA on depressive symptoms in this chapter of the video series.


References:
1. Latuda® (lurasidone HCl) prescribing information. Sunovion Pharmaceuticals Inc. February 2017.
2. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:160–168.
3. Data on file. Sunovion Pharmaceuticals Inc.
4. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:169–177.
5. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.
6. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73:159–171.

In patients with inadequate response to lithium or valproate, adding LATUDA significantly reduced depressive symptoms at Week 6 vs. placebo

latuda-efficacy-adjunctive-study-symptoms

 

  • In this study LATUDA was superior to placebo in reduction of MADRS scores at Week 61,4
  • LATUDA was also proven superior to placebo in the key secondary measure of CGI-BP scores1,4

*MADRS=Montgomery-Åsberg Depression Rating Scale.
Mixed model for repeated measures (MMRM) analysis.
Mean baseline MADRS scores: placebo: 30.8, LATUDA 20–120 mg/day: 30.6.
Mean dose (SD) for LATUDA was 66.3 (± 17.8) mg/day.3

 

Chapter 3: Efficacy

Dr. Joseph R. Calabrese, a psychiatrist specializing in mood disorders, discusses the effect of LATUDA on depressive symptoms in this chapter of the video series.

References:
1.
Latuda® (lurasidone HCl) prescribing information. Sunovion Pharmaceuticals Inc. February 2017.
2. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:160–168.
3. Data on file. Sunovion Pharmaceuticals Inc.
4. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:169–177.
5. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.
6. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73:159–171.

About MADRS

MADRS is a validated scale used to assess severity of depressive symptoms5

latuda-efficacy-rating-scales

Watch an expert discuss symptoms of Bipolar Depression

About CGI-BP

CGI-BP is a modification of the Clinical Global Impressions (CGI) scale designed to measure the severity of bipolar disorder6

latuda-efficacy-rating-cgibp
  • In applying this scale, the rater is asked to draw upon his or her clinical experience and compare the patient with other patients who have bipolar disorder

Watch an expert discuss symptoms of Bipolar Depression

 

 

References:
1. Latuda® (lurasidone HCl) prescribing information. Sunovion Pharmaceuticals Inc. February 2017.
2. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:160–168.
3. Data on file. Sunovion Pharmaceuticals Inc.
4. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:169–177.
5. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.
6. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73:159–171.

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR LATUDA

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Suicidal Thoughts and Behaviors
Antidepressants increased the risk of suicidal thoughts and behaviors in patients aged 24 years and younger. Monitor for clinical worsening and emergence of suicidal thoughts and behavior. LATUDA is not approved for use in pediatric patients with depression.

 

CONTRAINDICATIONS: LATUDA is contraindicated in the following:

Cerebrovascular Adverse Reactions, Including Stroke: In clinical trials, elderly subjects with dementia randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke. LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS): NMS is a potentially fatal symptom complex, reported with administration of antipsychotic drugs. Clinical signs of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Manage NMS with immediate discontinuation of antipsychotic drugs, including LATUDA, intensive symptomatic treatment, and monitoring.

Tardive Dyskinesia (TD): The risk of developing TD (a syndrome of abnormal involuntary movements) and the potential for it to become irreversible are believed to increase as the duration of treatment and total cumulative dose of antipsychotic increase. The syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established TD, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.

Metabolic Changes Atypical antipsychotic drugs have caused metabolic changes including:

Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Patients with diabetes should be regularly monitored for worsening of glucose control; those with risk factors for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Weight Gain: Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, LATUDA elevates prolactin levels. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.

Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia/neutropenia has been reported with antipsychotics. Agranulocytosis (including fatal cases) has been reported with other agents in the class. Monitor complete blood count in patients with a pre-existing low white blood cell count (WBC)/absolute neutrophil count (ANC) or history of drug-induced leukopenia/neutropenia. Discontinue LATUDA at the first sign of a decline in WBC in the absence of other causative factors.

Orthostatic Hypotension and Syncope: Atypical antipsychotics cause orthostatic hypotension and syncope. Generally, the risk is greatest at the beginning of treatment and when increasing the dose. Monitor patients vulnerable to hypotension and those with cardiovascular and cerebrovascular disease.

Falls: Antipsychotics may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls causing fractures or other injuries. For patients with disease, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating treatment and recurrently during therapy.

Seizures: LATUDA should be used cautiously in patients with a history of seizures or with conditions that lower seizure threshold.

Potential for Cognitive and Motor Impairment: Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.

Body Temperature Regulation: Use LATUDA with caution in patients who may experience conditions that increase body temperature (e.g., exercising strenuously, exposure to extreme heat, concomitant medication with anticholinergic activity, or being subject to dehydration).

Dysphagia: Antipsychotics, including LATUDA, have been associated with esophageal dysmotility and aspiration, and should be used with caution in patients at risk for aspiration pneumonia.

Most Commonly Observed Adverse Reactions: Commonly observed adverse reactions (≥5% incidence and at least twice the rate of placebo) for LATUDA:

To report SUSPECTED ADVERSE REACTIONS, contact Sunovion Pharmaceuticals Inc. at 877-737-7226 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Indications

LATUDA is indicated for:

Before prescribing LATUDA, please read the full Prescribing Information, including Boxed Warnings.